Rapid scfv evolution and high-yield pichia-secreted bispecific antibodies for allergen detection

Overview

This solution offers an integrated antibody development platform designed to overcome the limitations of traditional antibody production methods, which are often slow, costly, and difficult to scale. By combining high-throughput yeast ScFv display, iterative in vitro affinity maturation, and engineered Pichia pastoris expression strains, the platform enables rapid generation of high-affinity bispecific antibodies targeting food allergens and toxins including gluten, shellfish, and aflatoxins. The approach delivers faster development timelines, enhanced specificity and sensitivity, and scalable, cost-effective production suitable for diagnostic and detection applications.

Technical specifications

Key features and capabilities:

• Yeast ScFv display library screening using established synthetic and immune ScFv libraries for rapid identification of target-specific antibody fragments
• Iterative biopanning with allergen-cross-linked magnetic beads to enrich ScFvs with desired binding properties
• In vitro affinity maturation through error-prone random mutagenesis to generate sub-libraries and refine binding characteristics
• Surface plasmon resonance (SPR) analysis for quantitative measurement of binding kinetics and affinity
• Bispecific antibody construction in Fab or full-length formats using proprietary yeast antibody expression plasmids
• Engineered Pichia pastoris secretion strains optimized for high-yield, scalable antibody production at lower cost than conventional mammalian systems
• Dual-library strategy combining synthetic randomized and mouse immune-derived ScFv libraries for broader epitope coverage

Technology readiness level

The platform is built upon established Pichia surface display and antibody secretory systems already validated within the organization. The team has previously generated synthetic and mouse ScFv libraries and possesses the technical infrastructure for library construction, biopanning, affinity maturation, SPR characterization, and bispecific antibody engineering. Current activities focus on applying these validated capabilities to food allergen and toxin targets, with initial screening underway using existing libraries while parallel immune library generation is initiated. The next milestones include demonstrating high-affinity ScFv isolation, confirming bispecific construct expression and secretion in Pichia, and validating functional binding in final antibody formats.